Our AI
Privacy
15 minute meeting
To explore personalized outperforming therapies.
Our AI
Privacy
15 minute meeting
To explore personalized outperforming therapies.


RARE DISEASE
Trisomy 18
Trisomy 18
Trisomy 18
Synonyms: Chromosome 18 duplication, Edwards syndrome
Synonyms: Chromosome 18 duplication, Edwards syndrome
Synonyms: Chromosome 18 duplication, Edwards syndrome
Drug discovery
188
papers
On emerging therapies
Overview
Trisomy 18 (Edwards Syndrome) is a severe chromosomal disorder caused by trisomy of chromosome 18, characterized by congenital heart defects (90%+), growth restriction, neurodevelopmental delays, and multi-organ anomalies [1][7][10]. Prenatal mortality exceeds 95%, with median postnatal survival of 2.5-14.5 days; 5-10% survive beyond one year, requiring lifelong intensive care [1][7][16]. Profound intellectual disability and recurrent respiratory complications are universal in survivors [1][17].
Burden
Mortality: 90-95% infant mortality; 40% intrapartum death in term pregnancies [16][17].
Healthcare utilization: 42% hospitalization rate with interventions; 21% mortality in hospitalized cases (2016) [15].
Psychosocial impact: Profound family distress, complex decision-making, and lifelong care needs [6][8][17].
Therapies
Palliative care: Majority opt for comfort-focused management [1][16][17].
Targeted interventions: Selective cardiac surgery (10% of cases), gastrostomy (31.5% of hospitalized cases), and respiratory support [15][16].
Multidisciplinary care: Cardiology, physiotherapy, and feeding optimization [3][6][12].
Categories: rare abdominal surgical diseases, rare developmental anomalies during embryogenesis, rare genetic diseases, rare ophthalmic disorders, rare renal diseases, rare transplant-related disorders
Research Papers
188 drug discovery papers about Trisomy 18. Recent publications:
188 drug discovery papers about Trisomy 18. Recent publications:
categories:
Small molecules
cell therapies
2026-05-12 | Anesthetic management of a gross type C tracheoesophageal fistula by balloon catheter via tracheostoma in an infant with trisomy 18: A Case Report.
Gross Type C congenital esophageal atresia is associated with tracheoesophageal fistula (TEF). Perioperative airway management, including prevention of aspiration of gastric contents, is important. Generally, the TEF is blocked by 1-lung intubation of the dependent lung, or directly by insertion of a balloon catheter. This case report describes successful management of TEF by insertion of a balloon catheter via tracheostoma in an infant with a difficult airway. A boy with trisomy 18 underwent esophageal banding and gastrostomy for Gross Type C congenital esophageal atresia on postnatal day 3. Tracheostomy was performed on day 49, and definitive surgery for TEF was scheduled on day 83. The boy was diagnosed with Gross Type C congenital esophageal atresia shortly after birth. The patient was re-intubated orotracheally in the NICU. Oral insertion of a 4Fr Fogarty catheter to block the TEF was difficult. Insertion through the available tracheostoma was easier. We confirmed that the catheter could be guided to the TEF entrance using a bronchoscope, and the balloon was expanded to block the TEF. During surgery, there were no problems with airway management. In the management of TEF in children after tracheostomy, if oral insertion of the balloon catheter proves difficult, insertion via the tracheostoma may be effective.
2025-12-08 | Xenotransplantation and Disability Contraindications to Pediatric Heart Transplantation: Are We at the Horizon of Organ Transplantation for any Person That May Benefit?
If cardiac xenotransplantation (XTx) can resolve the critical shortage of human organs, then we have an ethical obligation to reconsider it for select pediatric patients who are currently ineligible for allotransplantation but who may still benefit from a transplanted organ. This is especially true for children with genetic diseases who are often excluded due to unfavorable risk-benefit assessments rooted in the scarcity of donor hearts. While the overall potential of XTx remains uncertain, its ability to mitigate scarcity forces us to reevaluate who might benefit from a transplant. This commentary argues that if XTx resolves at least some concerns regarding immediate organ availability and quantity, then we should support further evaluation for transplantation in pediatric patients who may benefit but who were previously deemed ineligible for cardiac allotransplantation. While not all patients may cross the risk-benefit threshold, many deserve at least this evaluation, and failing to even evaluate is rooted in disability bias. Primarily focusing on the precedent trisomy 21 (T21) patients and the evolution in perceptions of transplantation suitability, we argue that if these patients will physiologically be stable after XTx, then we should consider the benefits XTx could provide-prolonged survival, symptom resolution, and improved quality of life (QOL) even if baseline QOL is limited (as in patients with other disabilities)-as justifying the attendant risks. This argument may also extend beyond T21 to other patient populations with genetic conditions, including select patients with trisomy 18 (T18).
2025-10-29 | The developmental potential of mosaic embryos involving two chromosomes may not be inferior to that of sibling euploid blastocysts from the same cohort: clinical reflections and implications from an uncommon case.
Whether a mosaic blastocyst involving two chromosomes, each with a 45% mosaic level, can self-correct to a chromosomally normal and healthy individual post-implantation remains largely unexplored in the literature. A 35-year-old woman with unexplained infertility underwent in vitro fertilization (IVF) treatment. After multiple failed implantation attempts, one euploid female blastocyst and one mosaic male blastocyst (monosomy 11 (45%) and segmental monosomy 18 (45%) with a terminal segmental trisomy 18) were concurrently transferred in her final cycle. Of the two transferred blastocysts, only one successfully implanted. The pregnancy progressed uneventfully. Amniocentesis revealed a male fetus, indicating that the implanted blastocyst was the mosaic one. Reports of karyotype and array CGH of amniotic fluid revealed no abnormality. The patient delivered a healthy male infant at 37 + 5 weeks via spontaneous vaginal delivery. According to the COGEN position statement in 2017, mosaic blastocysts involving two or more chromosomes with mosaic levels exceeding 40% are typically ranked lowest for transfer. However, our case suggests that the implantation potential of mosaic embryos may be comparable to, if not greater than, that of their cohort euploid embryos when transferred within the same uterine environment. This observation raises the possibility that mosaic embryos possess a greater self-correction capacity than previously assumed, although further research is needed to substantiate this hypothesis.
2025-02-27 | Gastrostomy Tube Placement in Patients With Trisomy 13 and 18: Surgical Decision Making and Outcomes.
Trisomy 13 (T13) and trisomy 18 (T18) are chromosomal abnormalities which portend high rates of feeding dysfunction and infant mortality risk. Although gastrostomy tube (GT) placement is commonly performed in this population, there is limited data assessing outcomes associated with this procedure. Our aim was to determine survival outcomes among GT and non-GT patients with T13/18. We performed a retrospective cohort study of patients with T13 and T18 treated at our institution from 2005 through 2020. We compared baseline characteristics and survival data between GT and non-GT patients and performed multivariable survival analysis. We analyzed a total of 86 patients (23 GT, 63 non-GT). Over one-third of GT patients underwent the procedure during initial admission and most GTs were used for longer than one year (60.9 %). Significantly more GT patients survived initial discharge (87 % vs. 57.1 %, p < 0.001) and were alive at follow-up (43.5 % vs. 6.3 %, p < 0.001) compared to non-GT patients. Thirty-day post-discharge survival was determined solely by GT status and not impacted by predictors. GT patients had reduced overall mortality risk compared to non-GT patients in the first year of life (HR = 0.10 [95 % CI 0.04-0.29], p < 0.001) and during the fifteen-year study period (HR = 0.15 [95 % CI 0.06-0.35], p < 0.001). GT status predicted 30-day post-discharge survival in our cohort. GT patients had reduced overall mortality risk compared to non-GT patients. In patients with expected survival to initial discharge and feeding difficulty, GT placement at or after initial admission may be associated with improved survival outcomes. III.
2024-06-17 | Impact of definitive surgery for esophageal atresia on long-term outcomes in patients with trisomy 18.
This study investigates the long-term outcomes of palliative and definitive surgeries for esophageal atresia (EA) in patients with trisomy 18 syndrome. A retrospective study included 25 cases undergoing EA surgery at our center between 2008 and 2022. The Palliative group (n = 16) comprised 13 cases with esophageal banding and 3 with tracheoesophageal fistula (TEF) division. The Definitive group (n = 9) included 5 cases with primary repair and 4 with staged repair following TEF division. The patient characteristics exhibited no significant differences between the groups. In the Definitive group, 56% (5/9) were successfully weaned off mechanical ventilation, compared with none in the Palliative group (p = 0.002). Survival-to-discharge rates were 31% (5/16) in the Palliative group and 67% (6/9) in the Definitive group. Home ventilator management was required for all 5 cases that required ventilation in the Palliative group, whereas only 17% (1/6) in the Definitive group needed it. The Palliative group also required continuous oral suction for persistent saliva removal, with two cases undergoing laryngotracheal separation. Overall, definitive surgery for EA in patients with trisomy 18 syndrome may provide enhanced respiratory stability, thereby improving the survival-to-discharge rate and overall quality of life for patients and their families.
small molecules
2026-02-23 | Kawasaki Disease in a Child With Trisomy 18 Treated With Initial Combination Therapy, Including Cyclosporine.
Kawasaki disease is a systemic inflammatory disorder that is frequently encountered in routine pediatric clinical practice. Conversely, trisomy 18 is a chromosomal disorder with a historically poor prognosis. However, recent advances in medical care have improved its survival, with a reported 1-year survival rate reaching 29%. Despite this improvement, studies describing the clinical course of individuals with trisomy 18 beyond the first year of life remain scarce. Moreover, to our knowledge, cases of Kawasaki disease with trisomy 18 have not been reported. We report a case of a 3-year-11-month-old girl with trisomy 18 who presented with persistent fever and rash and, subsequently, fulfilled five of the six principal diagnostic criteria for Kawasaki disease. Because intravenous immunoglobulin resistance was predicted based on the Kobayashi score, initial treatment consisted of intravenous immunoglobulin (2 g/kg), aspirin, and oral cyclosporine concurrent with current Japanese guidelines. Defervescence was achieved without complications, and no adverse events were observed during treatment. No coronary artery abnormalities were observed during the acute phase or at 1-, 3-, and 6-month follow-up evaluations. We present a case of trisomy 18 treated according to Japanese guidelines for Kawasaki disease. Treatment regimen, which included cyclosporine, was safely administered, and the patient experienced a favorable clinical course. To improve the life expectancy of this patient group, it is crucial to accumulate comprehensive natural history, including the efficacy of standard treatments for various pediatric conditions. This will enable timely and appropriate therapeutic interventions.
2024-09-13 | Management and Outcomes of Hepatoblastoma in Patients With Trisomy 18: A Systematic Review and Pooled Analysis of 70 Patients.
Predicted 1-year survival of children with trisomy 18 (T18) has increased to 59.3%. We aimed to systematically review the characteristics, management, and outcomes of children with T18 and hepatoblastoma. A systematic literature review of the PubMed, Embase, Scopus, Web of Science, and Cochrane Library databases was performed according to the PRISMA 2020 statement (end-of-search date: 03/03/2024). Fifty studies reporting on 70 patients were included. The median age at diagnosis was 11.5 months, 85.9% were female (n = 55/64), and 15.0% had mosaic T18 (n = 6/40). Diagnosis was made during symptom evaluation (most commonly hepatomegaly or abdominal mass) in 45.5% (n = 15/33), incidentally in 24.2% (n = 8/33), during surveillance with abdominal ultrasound in 18.2% (n = 6/33), and at autopsy in 12.1% (n = 4/33). The median tumor size was 6.4 cm, 33.3% had multiple tumors (n = 14/42), and metastasis was present in one patient (3.8%; n = 1/26). Neoadjuvant chemotherapy was administered in 42.6% (n = 26/61) and adjuvant chemotherapy in 31.6% (n = 18/57). Surgical treatment was performed in 64.2% (n = 43/67). Of the patients not diagnosed on autopsy, overall mortality was 35.5% (n = 22/62) over a median follow-up of 11.0 months. Among the 26 deceased patients (including those diagnosed on autopsy), the most common causes of death were cardiopulmonary disease (38.5%, n = 10/26) and tumor progression (30.8%, n = 8/26). T18 does not preclude resection with curative intent for hepatoblastoma. Combination of surgery and chemotherapy should be considered in children on an individualized basis depending on tumor characteristics and underlying cardiopulmonary comorbidities. Locoregional modalities may have a role in the setting of severe comorbidities. Level IV evidence.
2024-08-14 | Surgery for hepatoblastoma in children with trisomy 18: a monocentric study.
Recently, children with trisomy 18 have been receiving more active treatment for malignancies. We report herein seven cases complete resection was achieved, and discuss multidisciplinary treatment for hepatoblastoma in patients with trisomy 18. The medical records of children with trisomy 18 who were treated at the study center between 2010 and 2023 were reviewed. Six of 69 patients had hepatoblastoma development, and three of these underwent multidisciplinary treatment. In addition, 6 patients had been referred by another hospital for treatment, and four of these underwent multidisciplinary treatment. Among the seven patients who underwent multidisciplinary treatment, three, two, and two were categorized in Pre-treatment Extent of Disease (PRETEXT) classification group I, II, and III, respectively. Neoadjuvant chemotherapy resulting in tumor reduction was performed in three cases. In all the cases, complete resection was achieved with pathologically safe margins. Perioperative complications included circulatory failure in one case and bile leakage in two cases. Adjuvant chemotherapy was administered in four cases. The postoperative observation period ranged from 3 months to 11 years, and all the patients are recurrence-free. Children with trisomy 18 complicated with hepatoblastoma whose cardiopulmonary conditions are stable may be good candidates for chemotherapy and surgery.
2023-03-14 | Seizures in trisomy 18: Prevalence, description, and treatment.
Changes in medical intervention over the last decade have improved outcomes for individuals with trisomy 18, the second most common human aneuploidy syndrome at birth. As children with trisomy 18 live longer, a shared concern of medical experts and parents is the occurrence and treatment of seizures. Previously published surveillance guidelines for this condition have not addressed seizure management. Using parent-reported data collected as part of the Tracking Rare Incidence Syndromes project, we report on the prevalence, course, and management of seizures in individuals with trisomy 18. Twenty-eight percent (52/186) of individuals diagnosed with trisomy 18 in our retrospective cohort experienced generalized, focal, or mixed seizures at some point in their lifetime. For many individuals, seizures were effectively managed by broad-spectrum anti-seizure medications. Correlation analysis showed that focal and generalized seizures were more likely to occur in individuals who had previously experienced infantile spasms or central apnea. Electroencephalogram testing should be considered as part of a standard screening approach in individuals with trisomy 18 to enable early diagnosis and treatment of seizures. An international registry that incorporates parent-reported and clinical data for patients with trisomy 18 may facilitate ongoing research and recruitment into clinical trials for seizure management.
2022-05-04 | Caffeine for the Treatment of Central Apnea in Trisomy 18: A Case Study in the Novel Use of Methylxanthines in Palliative Transport.
Central apnea is a major cause of death in neonates with trisomy 18 (T18) and is likely due to immaturity of the respiratory drive, similar to the pathological mechanism in apnea of prematurity. Although caffeine has long been used for apnea of prematurity, its use has not yet been reported for infants with T18. Here we describe an infant with T18 receiving comfort-focused care and palliative transport home. Of utmost importance to her family was enabling the patient to spend time at home before her death. However, immediately before transport, she developed severe central apnea, raising concern that she may not survive the transfer. Caffeine was trialed in the hopes of reducing central apnea events. Its use was successful and facilitated safe transport, allowing the patient to uneventfully transition home, where she spent several meaningful weeks with her family before her death.
proteins
2022-10-19 | Impact of Unconjugated estriol (uE3) assay interference on prenatal screening tests.
Unconjugated estriol (uE3) is an important biomarker in second trimester prenatal screening. Previous studies from our laboratory identified rare interference in the Beckman uE3 assay due to anti-ALP antibodies, which could be mitigated with a scavenger or heat-inactivated ALP (hALP). In the current study, 160 de-identified patient samples previously submitted for the Quad screen with low uE3 multiples of the median (MoM ≤0.50) were investigated for potential interference. A reagent pack spiking strategy with hALP was employed to understand if the interference could be identified and mitigated in a scalable manner. The 160 samples were measured using uE3 lot #920861 previously known to be subject to interference, lot #920861 spiked with hALP, and the vendor reformulated lot #922579. Samples were suspected to have interference if the percent difference in uE3 measurements was >50%. Pseudo-risks were calculated using a test patient environment to understand the screening impact due to the change in uE3 result. Seventeen of the 160 samples had uE3 results that were >50% different between the hALP spiked and non-spiked reagent pack. Both original lot #920861 with hALP and reformulated lot #922579 identified the same 17 patients as having interference in lot #920861. Analysis of screening risks using a test patient environment showed that assay interference could result in false positives for one trisomy 21 and three trisomy 18 post-test risk calculations. Our experiment of reagent pack spiking with hALP produced similar uE3 results to a reformulated reagent designed to address potential interference, demonstrating that this is a feasible strategy to screen for interference in a scalable manner. The vendor-provided reformulation addressed anti-ALP interference and improved the performance of the screen.
2021-06-15 | Survival Outcomes of Two-Stage Intracardiac Repair in Large Ventricular Septal Defect and Trisomy 18.
Surgical management has not been encouraged in patients with trisomy 18 (T18) and congenital heart diseases due to poor survival. This study aimed to investigate (1) the appropriateness of palliative surgeries followed by intracardiac repair (ICR) (i.e., two-stage ICR) for patients with a large ventricular septal defect (VSD) and T18, and (2) its impact on their long-term outcomes. Medical charts of patients with VSD and T18 who underwent two-stage ICR at the Japanese Red Cross Medical Center between January 2005 and December 2019 were retrospectively reviewed. Demographic data, timing, and types of palliative surgeries, information related to ICR, peri- and postoperative clinical information, postoperative survival, and cause of death were collected. The long-term prognosis of patients treated with two-stage ICR was compared with that of patients treated with primary ICR and palliative surgery without ICR. Overall, 18 (2 male, 16 female) patients underwent two-stage ICR. Pulmonary artery banding was the initial palliative surgery in all patients after a median duration of 19.5 (range 6-194) days of life. The median age and the mean body weight at the time of ICR were 18.2 (7.6-50.7) months and 6.0 ± 1.0 kg, respectively. The mean pulmonary artery pressure and pulmonary vascular resistance index before ICR were 19.1 ± 7.3 mmHg and 3.4 ± 2.0 U m2, respectively. Overall, 17/18 (94%) patients were discharged after ICR. Fourteen (78%) patients were alive during data collection. None of the patients died of cardiac insufficiency, and the median duration of survival was 46.3 (14.3-186.4) months since birth. Most patients required cardiac medications rather than pulmonary vasodilators at the last follow-up. During the study period, three patients underwent primary ICR, and 46 underwent palliative surgery without ICR. Of those who underwent primary ICR, two died in the hospital on the first and 48th day following ICR, and the third died 179 days after the ICR. The Log-rank test revealed a significantly longer survival for the patients treated with two-stage ICR compared with those treated with palliative surgery without ICR (P = 0.003). Two-stage ICR improves the long-term survival of patients with VSDs and T18. This safe surgical strategy can also prevent pulmonary hypertension in such patients.
2021-01-26 | Evaluation of Maternal Serum sHLA-G Levels for Trisomy 18 Fetuses Screening at Second Trimester
Human leukocyte antigen-G (HLA-G) has been widely acknowledged to play critical roles in fetal-maternal maintenance. However, the significance of using maternal serum sHLA-G to detect prenatal chromosomal abnormality has not been investigated. In China, prenatal screening using maternal α-fetoprotein (AFP), unconjugated estriol (uE3), and free β subunit human chorionic gonadotropin (β-hCG) in the second trimester has been widely applied. In this study, we evaluated the use of sHLA-G as a screening marker, compared with traditional second trimester prenatal screening. Serum samples from 1,019 singleton women in their second trimester were assessed. Among them, 139 infants were confirmed with trisomy 21 (T21) by karyotyping, 83 were confirmed with trisomy 18 (T18), and the remaining 797 infants had no abnormalities. The sHLA-G levels in maternal sera were significantly lower in pregnant women with T18 fetuses (median: 47.8 U/ml, range: 9.8–234.2 U/ml) and significantly higher in those with T21 fetuses (median: 125.7 U/ml, range: 28.7–831.7 U/ml), compared with the normal controls (median: 106.3 U/ml, range: 50.5–1136.4 U/ml) ( p < 0.001). The risk values of the screening of T21 or T18 fetuses were assessed using mean and standard deviation log 10 analyte multiples of median (MoM) which showed that the predictive values of sHLA-G were the same as free β-hCG, and superior to AFP and uE3 for T18 screening. Logistic regression analysis revealed that sHLA-G MoM was the highest risk factor associated with pregnant women carrying T18 fetuses [Exp(B): 171.26, 95% CI: 36.30–807.97, p < 0.001]. Receiver operating characteristic (ROC) analysis revealed that the area under ROC curve for sHLA-G MoM was 0.915 (95% CI, 0.871–0.959, p < 0.001), for AFP MoM was 0.796 (95% CI, 0.730–0.861, p < 0.001), for free β-hCG MoM was 0.881 (95% CI, 0.829–0.934, p < 0.001), and for uE3 MoM was 0.876 (95% CI, 0.828–0.923, p < 0.001) in the T18 group. sHLA-G MoM demonstrated the best sensitivity and negative predictive value. For the first time, our findings reveal that sHLA-G is a better second trimester screening marker for the detection of T18 fetuses and the combined application of sHLA-G with AFP, free β-hCG, and uE3 could improve clinical screening for T18 fetuses.
2019-08-15 | [Genotypic and phenotypic analysis of a patient with de novo partial monosomy 18p and partial trisomy 18q].
To explore the genetic cause for a patient with intellectual disability, short stature and multiple congenital anomalies, and to correlate the result with the clinical phenotype. Routine karyotyping analysis was carried out on GTG-banded metaphase chromosomes. Single nucleotide polymorphism (SNP) microarray was used to detect microdeletions or microduplications in the patient. Fluorescence in situ hybridization (FISH) was used to ascertain the origin of aberrant chromosomes. The karyotype of the patient was 46,XY,der(18), while both of his parents had a normal karyotype. SNP array identified a 1.23 Mb deletion at 18p11.32-pter (chr18: 136 227-1 370 501, hg19) and a 33.76 Mb duplication at 18q21.1-qter (chr18: 44 250 359-78 013 728, hg19) in the patient. Above finding was confirmed by dual-color FISH with one color for 18p and another for 18q. The patient presented with some common features of 18p deletion and 18q duplication including intellectual disability and growth retardation, in addition with some features of 18p deletion including pectus excavatum, short stature and growth hormone (GH) deficiency. The patient showed progressive improvement of stature with GH therapy. Comparison of patients with previously reported dup(18q)+del(18p) recombinations suggested that, even for patients with similar breakpoints, their phenotypes have ranged from normal to severe and there were no consistent findings. As aberrations involving double chromosomal segments often result in phenotypic variability, it has been difficult to correlate the genotype of our patient with his phenotype.
2009-10-20 | Placental protein 13 as a first trimester screening marker for aneuploidy
Abstract Objective To determine whether Placental Protein 13 (PP13) could be an additional marker in first trimester screening for aneuploidies. Methods To evaluate differences in multiples of the gestation‐specific normal median (MoMs), PP13 concentrations were measured in serum samples from Down syndrome, trisomy 18 and 13 affected pregnancies and euploid singleton pregnancies (four for each case matched for duration of storage, maternal weight and age). Results The PP13 MoM in Down syndrome cases ( n = 153) was 0.91 [not statistically significant from controls ( n = 853); P = 0.06; Wilcoxon rank sum test, two‐tail]. PP13 MoMs were decreased in trisomy 18 ( n = 38—median MoM 0.64; P < 0.0001) and trisomy 13 cases ( n = 23—median MoM 0.46; P < 0.0001). There was a slight upward trend in MoM values of the Down syndrome cases with gestational weeks. The PP13 MoM was significantly correlated with the pregnancy associated plasma protein‐A MoM and the free β‐subunit of human chorion gonadotrophin (fβ‐hCG) MoM. Conclusion PP13 does not seem to be a good marker for Down syndrome. PP13 MoMs are, however, significantly lower in trisomy 18 and 13 pregnancies. The addition of PP13 to the current screening test could be valuable for improving the discrimination of aneuploid from euploid pregnancies. Copyright © 2009 John Wiley & Sons, Ltd.
gene therapies
2026-08-19 | Chromosomal and genetic anomalies in fetuses with nuchal translucency between 3.0 and 3.4 mm: A systematic review and meta-analysis.
To report the prevalence of chromosomal anomalies in fetuses with a nuchal translucency (NT) between 3.0 and 3.4 mm and to assess the incremental yield of invasive prenatal diagnosis over cell-free DNA (cfDNA) in these fetuses. MEDLINE, EMBASE, and The Cochrane Library were searched. Inclusion criteria encompassed fetuses with an NT between 3.0 and 3.4 mm undergoing prenatal invasive testing or postnatal genetic assessment. The observed outcomes included common trisomies such as Trisomy 21, 18, and 13, sex chromosomal anomalies (SCAs), rare autosomal anomalies, copy number variants detected by chromosomal microarray (CMA), and single-gene disorders. We also reported the rate of anomalies potentially detectable by cfDNA. Finally, we planned to perform a subgroup analysis involving cases with isolated NT between 3.0 and 3.4 mm, including only cases undergoing detailed first-trimester ultrasound assessment. A random-effects meta-analysis of proportions was utilized to analyze the data. Seventeen studies (7007 fetuses) were included. In fetuses with NT measurements between 3.0 and 3.4 mm, chromosomal anomalies were identified in 13.1% (95% CI 9.3-17.3). Common trisomies included Trisomy 21 at 8.0% (95% CI 5.1-11.5), Trisomy 18 at 1.0% (95% CI 0.6-1.7), and Trisomy 13 at 0.52% (95% CI 0.2-1.0) of all chromosomal anomalies. SCAs occurred in 0.58% (95% CI 0.4-0.8), while rare autosomal trisomies and pathogenic or likely pathogenic copy number variants (CNVs) were found in 0.27% (95% CI 0.1-0.6) and 2.5% (95% CI 1.3-3.9), respectively. Additionally, single-gene disorders detected via NGS/WES were reported in 5.7% (95% CI 3.3-8) of cases with NT between 3.0 and 3.4 mm. When examining only fetuses with an isolated NT between 3.0 and 3.4 mm, all chromosomal anomalies were identified in 12.4% (95% CI 7.9-17.7). Fetuses with an NT between 3.0 and 3.4 mm showed a high rate of chromosomal anomalies and CNVs, most of which could potentially be detected through cfDNA.
2026-05-08 | Embryonic reference values for nuchal translucency thickness and ductus venosus blood flow at 8-10 + 6 gestational weeks.
To measure embryonic nuchal translucency (NT) thickness and ductus venosus (DV) blood flow indices using transvaginal two-dimensional sonography and Doppler ultrasound at 8-10 + 6 weeks. Transvaginal scans were performed for 149 normal and three abnormal embryos (trisomy 18 with ventricular septal defect (VSD), tricuspid insufficiency (TR), and intrauterine fetal death with trisomy 21) at 8-10 + 6 weeks. NT thickness, S wave (cm/s), D wave (cm/s), "a" wave (cm/s), S/a, pulsatility index (PI), and resistance index (RI) of DV were measured, and reference values for each parameter were determined. NT, S, D, S/a, PI, and RI increased linearly with advancing gestation (p < 0.01). The 'a' (mean, 5.55 cm/s; SD, 1.8 cm/s) value was constant at 8-10 + 6 weeks of gestation. There were significant linear correlations between NT, S, D, S/a, PI, and RI, and crown-rump length (CRL) (p < 0.01). The "a" value remained unchanged with increasing CRL during this period. NT thickness (2.8 mm) in the trisomy 18 patient with VSD was high at 10 + 6 weeks, and reversed "a" wave was evident in the patient with TR at 10 + 1 weeks. In a fetus with intrauterine fetal death with trisomy 21 at 11 weeks and 6 days, NT thickness was 2.1 mm, and reversed DV flow was noted at 9 weeks and 6 days. Our results provide reference values for NT thickness and DV flow parameters, which may advance our understanding of embryonic growth and promote earlier prenatal diagnosis of chromosome abnormalities and/or cardiac anomalies before 11 weeks.
2026-03-24 | Interplay between DYRK1A dosage and aneuploidy-induced neuropathology in Down syndrome
A reduction in the number of neurons and an increased susceptibility to apoptosis are one of the characteristic features observed in Down syndrome (DS). However, the multifaceted actions of chromosomal aneuploidy hinder the elucidation of the underlying mechanism. Here, using neurons and astrocytes differentiated from patient-derived induced pluripotent stem cells (iPSCs), we aimed to clarify the neuropathology of DS by focusing on aneuploidy-associated stress and the dosage effects of specific genes. Human chromosomal trisomies 13, 18, and 21 exert a stress response on neurons, resulting in the accumulation of protein aggregates. In addition, DYRK1A overdosage in trisomy 21 astrocytes causes intrinsic activation of the NLRP3 inflammasome, which leads to the release of inflammatory cytokines. These dual actions reciprocally interact and enhance neuronal apoptosis in trisomy 21. Notably, correction of DYRK1A copy number successfully rescued apoptotic neural death in combination with a chemical chaperone treatment. Our study provides insights into the neuropathological mechanism of DS and its potential therapeutic strategy.
2026-02-09 | Maternal mixed UPD3 and a homozygous PLXNA1 c.2497G>C variant in a fetus with severe anomalies.
Non-invasive prenatal testing (NIPT) is widely used for screening common fetal aneuploidies such as trisomy 21 (T21), trisomy 18 (T18), and trisomy 13 (T13). However, its utility in detecting trisomy 3 (T3) has been rarely reported. Furthermore, uniparental disomy (UPD) involving chromosome 3 is a rare genetic condition with potential phenotypic consequences. NIPT indicated a high risk for fetal T3. This finding was further investigated using copy number variation (CNV) analysis via trio-based chromosomal microarray analysis (trio-CMA). Subsequent trio-based whole-genome sequencing (trio-WGS) identified a homozygous variant in PLXNA1 associated with a putative autosomal recessive disorder in the fetus. The detected variant was validated by Sanger sequencing in the parents. NIPT revealed a fetal Z-score (27.22) for T3. Trio-CMA ruled out T3 but confirmed mixed maternal UPD3. Trio-WGS identified a homozygous PLXNA1 variant (NM_032242.3:c.2497G>C, p.Ala833Pro) in the fetus, inherited from the heterozygous mother. The observed severe fetal phenotype was partial consistent with the molecular findings of mixed UPD3 and the homozygous PLXNA1 variant, indicating that this variant may represent a potential pathogenic cause. While NIPT can signal a high risk for rare aneuploidies, definitive diagnosis requires invasive prenatal testing. Discrepancies between NIPT and fetal tissue analyses may arise from confined placental mosaicism (CPM). We propose a model in which nondisjunction of chromosome 3 during germ cell formation led to trisomy, followed by a postzygotic self-correction event, resulting in mixed maternal UPD3 and increased risk of autosomal recessive disorders.
2026-01-01 | Frequency of chromosomal alterations identified in peripheral blood karyotypes at the genetics and genomics Laboratory of Hospital del Niño Dr. José Renán Esquivel (2015–2019)
To describe the chromosomal alterations found in peripheral blood karyotypes performed at the Genetics and Genomics Laboratory of the Hospital del Niño of Panama, Dr. José Renán Esquivel, during the years 2015 to 2019. A descriptive, cross-sectional study with a quantitative approach was conducted. During this period, a total of 835 chromosomal analyses were performed on peripheral blood lymphocytes. Of these, 336 patients presented some type of chromosomal alteration. Among them, 85% (285 patients) had numerical chromosomal alterations, while 15% (51 patients) had structural chromosomal alterations, with numerical alterations being the most frequent. Among numerical alterations, Trisomy 21 (Down Syndrome) was the most common, representing 85% of these cases. Other alterations included Turner Syndrome (5%), Trisomy 13 (4%), Trisomy 18 (3%), and less frequently, Klinefelter Syndrome and mosaicism cases (1%). Regarding structural chromosomal alterations, the most frequent were Robertsonian translocations (31%), followed by heterochromatin+ (20%), deletions (16%), and inversions (12%). Less common alterations included duplications, isochromosomes, additional material, insertions, and fragile sites. The findings of this study partially align with previous research conducted in Argentina (Aiassa and Gorlat, 2010) and Chile (Estay et al., 2007). These studies also reported a predominance of numerical alterations, particularly Trisomy 21. However, differences were observed in the frequency of structural alterations: deletions were more common in Argentina, whereas translocations were more frequent in Chile and Panama. Numerical chromosomal alterations, particularly Trisomy 21, were the most common in the studied population, highlighting the importance of early cytogenetic diagnosis in pediatric patients.
cell therapies
2026-05-12 | Anesthetic management of a gross type C tracheoesophageal fistula by balloon catheter via tracheostoma in an infant with trisomy 18: A Case Report.
Gross Type C congenital esophageal atresia is associated with tracheoesophageal fistula (TEF). Perioperative airway management, including prevention of aspiration of gastric contents, is important. Generally, the TEF is blocked by 1-lung intubation of the dependent lung, or directly by insertion of a balloon catheter. This case report describes successful management of TEF by insertion of a balloon catheter via tracheostoma in an infant with a difficult airway. A boy with trisomy 18 underwent esophageal banding and gastrostomy for Gross Type C congenital esophageal atresia on postnatal day 3. Tracheostomy was performed on day 49, and definitive surgery for TEF was scheduled on day 83. The boy was diagnosed with Gross Type C congenital esophageal atresia shortly after birth. The patient was re-intubated orotracheally in the NICU. Oral insertion of a 4Fr Fogarty catheter to block the TEF was difficult. Insertion through the available tracheostoma was easier. We confirmed that the catheter could be guided to the TEF entrance using a bronchoscope, and the balloon was expanded to block the TEF. During surgery, there were no problems with airway management. In the management of TEF in children after tracheostomy, if oral insertion of the balloon catheter proves difficult, insertion via the tracheostoma may be effective.
2025-12-08 | Xenotransplantation and Disability Contraindications to Pediatric Heart Transplantation: Are We at the Horizon of Organ Transplantation for any Person That May Benefit?
If cardiac xenotransplantation (XTx) can resolve the critical shortage of human organs, then we have an ethical obligation to reconsider it for select pediatric patients who are currently ineligible for allotransplantation but who may still benefit from a transplanted organ. This is especially true for children with genetic diseases who are often excluded due to unfavorable risk-benefit assessments rooted in the scarcity of donor hearts. While the overall potential of XTx remains uncertain, its ability to mitigate scarcity forces us to reevaluate who might benefit from a transplant. This commentary argues that if XTx resolves at least some concerns regarding immediate organ availability and quantity, then we should support further evaluation for transplantation in pediatric patients who may benefit but who were previously deemed ineligible for cardiac allotransplantation. While not all patients may cross the risk-benefit threshold, many deserve at least this evaluation, and failing to even evaluate is rooted in disability bias. Primarily focusing on the precedent trisomy 21 (T21) patients and the evolution in perceptions of transplantation suitability, we argue that if these patients will physiologically be stable after XTx, then we should consider the benefits XTx could provide-prolonged survival, symptom resolution, and improved quality of life (QOL) even if baseline QOL is limited (as in patients with other disabilities)-as justifying the attendant risks. This argument may also extend beyond T21 to other patient populations with genetic conditions, including select patients with trisomy 18 (T18).
2025-10-29 | The developmental potential of mosaic embryos involving two chromosomes may not be inferior to that of sibling euploid blastocysts from the same cohort: clinical reflections and implications from an uncommon case.
Whether a mosaic blastocyst involving two chromosomes, each with a 45% mosaic level, can self-correct to a chromosomally normal and healthy individual post-implantation remains largely unexplored in the literature. A 35-year-old woman with unexplained infertility underwent in vitro fertilization (IVF) treatment. After multiple failed implantation attempts, one euploid female blastocyst and one mosaic male blastocyst (monosomy 11 (45%) and segmental monosomy 18 (45%) with a terminal segmental trisomy 18) were concurrently transferred in her final cycle. Of the two transferred blastocysts, only one successfully implanted. The pregnancy progressed uneventfully. Amniocentesis revealed a male fetus, indicating that the implanted blastocyst was the mosaic one. Reports of karyotype and array CGH of amniotic fluid revealed no abnormality. The patient delivered a healthy male infant at 37 + 5 weeks via spontaneous vaginal delivery. According to the COGEN position statement in 2017, mosaic blastocysts involving two or more chromosomes with mosaic levels exceeding 40% are typically ranked lowest for transfer. However, our case suggests that the implantation potential of mosaic embryos may be comparable to, if not greater than, that of their cohort euploid embryos when transferred within the same uterine environment. This observation raises the possibility that mosaic embryos possess a greater self-correction capacity than previously assumed, although further research is needed to substantiate this hypothesis.
2025-02-27 | Gastrostomy Tube Placement in Patients With Trisomy 13 and 18: Surgical Decision Making and Outcomes.
Trisomy 13 (T13) and trisomy 18 (T18) are chromosomal abnormalities which portend high rates of feeding dysfunction and infant mortality risk. Although gastrostomy tube (GT) placement is commonly performed in this population, there is limited data assessing outcomes associated with this procedure. Our aim was to determine survival outcomes among GT and non-GT patients with T13/18. We performed a retrospective cohort study of patients with T13 and T18 treated at our institution from 2005 through 2020. We compared baseline characteristics and survival data between GT and non-GT patients and performed multivariable survival analysis. We analyzed a total of 86 patients (23 GT, 63 non-GT). Over one-third of GT patients underwent the procedure during initial admission and most GTs were used for longer than one year (60.9 %). Significantly more GT patients survived initial discharge (87 % vs. 57.1 %, p < 0.001) and were alive at follow-up (43.5 % vs. 6.3 %, p < 0.001) compared to non-GT patients. Thirty-day post-discharge survival was determined solely by GT status and not impacted by predictors. GT patients had reduced overall mortality risk compared to non-GT patients in the first year of life (HR = 0.10 [95 % CI 0.04-0.29], p < 0.001) and during the fifteen-year study period (HR = 0.15 [95 % CI 0.06-0.35], p < 0.001). GT status predicted 30-day post-discharge survival in our cohort. GT patients had reduced overall mortality risk compared to non-GT patients. In patients with expected survival to initial discharge and feeding difficulty, GT placement at or after initial admission may be associated with improved survival outcomes. III.
2024-06-17 | Impact of definitive surgery for esophageal atresia on long-term outcomes in patients with trisomy 18.
This study investigates the long-term outcomes of palliative and definitive surgeries for esophageal atresia (EA) in patients with trisomy 18 syndrome. A retrospective study included 25 cases undergoing EA surgery at our center between 2008 and 2022. The Palliative group (n = 16) comprised 13 cases with esophageal banding and 3 with tracheoesophageal fistula (TEF) division. The Definitive group (n = 9) included 5 cases with primary repair and 4 with staged repair following TEF division. The patient characteristics exhibited no significant differences between the groups. In the Definitive group, 56% (5/9) were successfully weaned off mechanical ventilation, compared with none in the Palliative group (p = 0.002). Survival-to-discharge rates were 31% (5/16) in the Palliative group and 67% (6/9) in the Definitive group. Home ventilator management was required for all 5 cases that required ventilation in the Palliative group, whereas only 17% (1/6) in the Definitive group needed it. The Palliative group also required continuous oral suction for persistent saliva removal, with two cases undergoing laryngotracheal separation. Overall, definitive surgery for EA in patients with trisomy 18 syndrome may provide enhanced respiratory stability, thereby improving the survival-to-discharge rate and overall quality of life for patients and their families.
small molecules
2026-02-23 | Kawasaki Disease in a Child With Trisomy 18 Treated With Initial Combination Therapy, Including Cyclosporine.
Kawasaki disease is a systemic inflammatory disorder that is frequently encountered in routine pediatric clinical practice. Conversely, trisomy 18 is a chromosomal disorder with a historically poor prognosis. However, recent advances in medical care have improved its survival, with a reported 1-year survival rate reaching 29%. Despite this improvement, studies describing the clinical course of individuals with trisomy 18 beyond the first year of life remain scarce. Moreover, to our knowledge, cases of Kawasaki disease with trisomy 18 have not been reported. We report a case of a 3-year-11-month-old girl with trisomy 18 who presented with persistent fever and rash and, subsequently, fulfilled five of the six principal diagnostic criteria for Kawasaki disease. Because intravenous immunoglobulin resistance was predicted based on the Kobayashi score, initial treatment consisted of intravenous immunoglobulin (2 g/kg), aspirin, and oral cyclosporine concurrent with current Japanese guidelines. Defervescence was achieved without complications, and no adverse events were observed during treatment. No coronary artery abnormalities were observed during the acute phase or at 1-, 3-, and 6-month follow-up evaluations. We present a case of trisomy 18 treated according to Japanese guidelines for Kawasaki disease. Treatment regimen, which included cyclosporine, was safely administered, and the patient experienced a favorable clinical course. To improve the life expectancy of this patient group, it is crucial to accumulate comprehensive natural history, including the efficacy of standard treatments for various pediatric conditions. This will enable timely and appropriate therapeutic interventions.
2024-09-13 | Management and Outcomes of Hepatoblastoma in Patients With Trisomy 18: A Systematic Review and Pooled Analysis of 70 Patients.
Predicted 1-year survival of children with trisomy 18 (T18) has increased to 59.3%. We aimed to systematically review the characteristics, management, and outcomes of children with T18 and hepatoblastoma. A systematic literature review of the PubMed, Embase, Scopus, Web of Science, and Cochrane Library databases was performed according to the PRISMA 2020 statement (end-of-search date: 03/03/2024). Fifty studies reporting on 70 patients were included. The median age at diagnosis was 11.5 months, 85.9% were female (n = 55/64), and 15.0% had mosaic T18 (n = 6/40). Diagnosis was made during symptom evaluation (most commonly hepatomegaly or abdominal mass) in 45.5% (n = 15/33), incidentally in 24.2% (n = 8/33), during surveillance with abdominal ultrasound in 18.2% (n = 6/33), and at autopsy in 12.1% (n = 4/33). The median tumor size was 6.4 cm, 33.3% had multiple tumors (n = 14/42), and metastasis was present in one patient (3.8%; n = 1/26). Neoadjuvant chemotherapy was administered in 42.6% (n = 26/61) and adjuvant chemotherapy in 31.6% (n = 18/57). Surgical treatment was performed in 64.2% (n = 43/67). Of the patients not diagnosed on autopsy, overall mortality was 35.5% (n = 22/62) over a median follow-up of 11.0 months. Among the 26 deceased patients (including those diagnosed on autopsy), the most common causes of death were cardiopulmonary disease (38.5%, n = 10/26) and tumor progression (30.8%, n = 8/26). T18 does not preclude resection with curative intent for hepatoblastoma. Combination of surgery and chemotherapy should be considered in children on an individualized basis depending on tumor characteristics and underlying cardiopulmonary comorbidities. Locoregional modalities may have a role in the setting of severe comorbidities. Level IV evidence.
2024-08-14 | Surgery for hepatoblastoma in children with trisomy 18: a monocentric study.
Recently, children with trisomy 18 have been receiving more active treatment for malignancies. We report herein seven cases complete resection was achieved, and discuss multidisciplinary treatment for hepatoblastoma in patients with trisomy 18. The medical records of children with trisomy 18 who were treated at the study center between 2010 and 2023 were reviewed. Six of 69 patients had hepatoblastoma development, and three of these underwent multidisciplinary treatment. In addition, 6 patients had been referred by another hospital for treatment, and four of these underwent multidisciplinary treatment. Among the seven patients who underwent multidisciplinary treatment, three, two, and two were categorized in Pre-treatment Extent of Disease (PRETEXT) classification group I, II, and III, respectively. Neoadjuvant chemotherapy resulting in tumor reduction was performed in three cases. In all the cases, complete resection was achieved with pathologically safe margins. Perioperative complications included circulatory failure in one case and bile leakage in two cases. Adjuvant chemotherapy was administered in four cases. The postoperative observation period ranged from 3 months to 11 years, and all the patients are recurrence-free. Children with trisomy 18 complicated with hepatoblastoma whose cardiopulmonary conditions are stable may be good candidates for chemotherapy and surgery.
2023-03-14 | Seizures in trisomy 18: Prevalence, description, and treatment.
Changes in medical intervention over the last decade have improved outcomes for individuals with trisomy 18, the second most common human aneuploidy syndrome at birth. As children with trisomy 18 live longer, a shared concern of medical experts and parents is the occurrence and treatment of seizures. Previously published surveillance guidelines for this condition have not addressed seizure management. Using parent-reported data collected as part of the Tracking Rare Incidence Syndromes project, we report on the prevalence, course, and management of seizures in individuals with trisomy 18. Twenty-eight percent (52/186) of individuals diagnosed with trisomy 18 in our retrospective cohort experienced generalized, focal, or mixed seizures at some point in their lifetime. For many individuals, seizures were effectively managed by broad-spectrum anti-seizure medications. Correlation analysis showed that focal and generalized seizures were more likely to occur in individuals who had previously experienced infantile spasms or central apnea. Electroencephalogram testing should be considered as part of a standard screening approach in individuals with trisomy 18 to enable early diagnosis and treatment of seizures. An international registry that incorporates parent-reported and clinical data for patients with trisomy 18 may facilitate ongoing research and recruitment into clinical trials for seizure management.
2022-05-04 | Caffeine for the Treatment of Central Apnea in Trisomy 18: A Case Study in the Novel Use of Methylxanthines in Palliative Transport.
Central apnea is a major cause of death in neonates with trisomy 18 (T18) and is likely due to immaturity of the respiratory drive, similar to the pathological mechanism in apnea of prematurity. Although caffeine has long been used for apnea of prematurity, its use has not yet been reported for infants with T18. Here we describe an infant with T18 receiving comfort-focused care and palliative transport home. Of utmost importance to her family was enabling the patient to spend time at home before her death. However, immediately before transport, she developed severe central apnea, raising concern that she may not survive the transfer. Caffeine was trialed in the hopes of reducing central apnea events. Its use was successful and facilitated safe transport, allowing the patient to uneventfully transition home, where she spent several meaningful weeks with her family before her death.
proteins
2022-10-19 | Impact of Unconjugated estriol (uE3) assay interference on prenatal screening tests.
Unconjugated estriol (uE3) is an important biomarker in second trimester prenatal screening. Previous studies from our laboratory identified rare interference in the Beckman uE3 assay due to anti-ALP antibodies, which could be mitigated with a scavenger or heat-inactivated ALP (hALP). In the current study, 160 de-identified patient samples previously submitted for the Quad screen with low uE3 multiples of the median (MoM ≤0.50) were investigated for potential interference. A reagent pack spiking strategy with hALP was employed to understand if the interference could be identified and mitigated in a scalable manner. The 160 samples were measured using uE3 lot #920861 previously known to be subject to interference, lot #920861 spiked with hALP, and the vendor reformulated lot #922579. Samples were suspected to have interference if the percent difference in uE3 measurements was >50%. Pseudo-risks were calculated using a test patient environment to understand the screening impact due to the change in uE3 result. Seventeen of the 160 samples had uE3 results that were >50% different between the hALP spiked and non-spiked reagent pack. Both original lot #920861 with hALP and reformulated lot #922579 identified the same 17 patients as having interference in lot #920861. Analysis of screening risks using a test patient environment showed that assay interference could result in false positives for one trisomy 21 and three trisomy 18 post-test risk calculations. Our experiment of reagent pack spiking with hALP produced similar uE3 results to a reformulated reagent designed to address potential interference, demonstrating that this is a feasible strategy to screen for interference in a scalable manner. The vendor-provided reformulation addressed anti-ALP interference and improved the performance of the screen.
2021-06-15 | Survival Outcomes of Two-Stage Intracardiac Repair in Large Ventricular Septal Defect and Trisomy 18.
Surgical management has not been encouraged in patients with trisomy 18 (T18) and congenital heart diseases due to poor survival. This study aimed to investigate (1) the appropriateness of palliative surgeries followed by intracardiac repair (ICR) (i.e., two-stage ICR) for patients with a large ventricular septal defect (VSD) and T18, and (2) its impact on their long-term outcomes. Medical charts of patients with VSD and T18 who underwent two-stage ICR at the Japanese Red Cross Medical Center between January 2005 and December 2019 were retrospectively reviewed. Demographic data, timing, and types of palliative surgeries, information related to ICR, peri- and postoperative clinical information, postoperative survival, and cause of death were collected. The long-term prognosis of patients treated with two-stage ICR was compared with that of patients treated with primary ICR and palliative surgery without ICR. Overall, 18 (2 male, 16 female) patients underwent two-stage ICR. Pulmonary artery banding was the initial palliative surgery in all patients after a median duration of 19.5 (range 6-194) days of life. The median age and the mean body weight at the time of ICR were 18.2 (7.6-50.7) months and 6.0 ± 1.0 kg, respectively. The mean pulmonary artery pressure and pulmonary vascular resistance index before ICR were 19.1 ± 7.3 mmHg and 3.4 ± 2.0 U m2, respectively. Overall, 17/18 (94%) patients were discharged after ICR. Fourteen (78%) patients were alive during data collection. None of the patients died of cardiac insufficiency, and the median duration of survival was 46.3 (14.3-186.4) months since birth. Most patients required cardiac medications rather than pulmonary vasodilators at the last follow-up. During the study period, three patients underwent primary ICR, and 46 underwent palliative surgery without ICR. Of those who underwent primary ICR, two died in the hospital on the first and 48th day following ICR, and the third died 179 days after the ICR. The Log-rank test revealed a significantly longer survival for the patients treated with two-stage ICR compared with those treated with palliative surgery without ICR (P = 0.003). Two-stage ICR improves the long-term survival of patients with VSDs and T18. This safe surgical strategy can also prevent pulmonary hypertension in such patients.
2021-01-26 | Evaluation of Maternal Serum sHLA-G Levels for Trisomy 18 Fetuses Screening at Second Trimester
Human leukocyte antigen-G (HLA-G) has been widely acknowledged to play critical roles in fetal-maternal maintenance. However, the significance of using maternal serum sHLA-G to detect prenatal chromosomal abnormality has not been investigated. In China, prenatal screening using maternal α-fetoprotein (AFP), unconjugated estriol (uE3), and free β subunit human chorionic gonadotropin (β-hCG) in the second trimester has been widely applied. In this study, we evaluated the use of sHLA-G as a screening marker, compared with traditional second trimester prenatal screening. Serum samples from 1,019 singleton women in their second trimester were assessed. Among them, 139 infants were confirmed with trisomy 21 (T21) by karyotyping, 83 were confirmed with trisomy 18 (T18), and the remaining 797 infants had no abnormalities. The sHLA-G levels in maternal sera were significantly lower in pregnant women with T18 fetuses (median: 47.8 U/ml, range: 9.8–234.2 U/ml) and significantly higher in those with T21 fetuses (median: 125.7 U/ml, range: 28.7–831.7 U/ml), compared with the normal controls (median: 106.3 U/ml, range: 50.5–1136.4 U/ml) ( p < 0.001). The risk values of the screening of T21 or T18 fetuses were assessed using mean and standard deviation log 10 analyte multiples of median (MoM) which showed that the predictive values of sHLA-G were the same as free β-hCG, and superior to AFP and uE3 for T18 screening. Logistic regression analysis revealed that sHLA-G MoM was the highest risk factor associated with pregnant women carrying T18 fetuses [Exp(B): 171.26, 95% CI: 36.30–807.97, p < 0.001]. Receiver operating characteristic (ROC) analysis revealed that the area under ROC curve for sHLA-G MoM was 0.915 (95% CI, 0.871–0.959, p < 0.001), for AFP MoM was 0.796 (95% CI, 0.730–0.861, p < 0.001), for free β-hCG MoM was 0.881 (95% CI, 0.829–0.934, p < 0.001), and for uE3 MoM was 0.876 (95% CI, 0.828–0.923, p < 0.001) in the T18 group. sHLA-G MoM demonstrated the best sensitivity and negative predictive value. For the first time, our findings reveal that sHLA-G is a better second trimester screening marker for the detection of T18 fetuses and the combined application of sHLA-G with AFP, free β-hCG, and uE3 could improve clinical screening for T18 fetuses.
2019-08-15 | [Genotypic and phenotypic analysis of a patient with de novo partial monosomy 18p and partial trisomy 18q].
To explore the genetic cause for a patient with intellectual disability, short stature and multiple congenital anomalies, and to correlate the result with the clinical phenotype. Routine karyotyping analysis was carried out on GTG-banded metaphase chromosomes. Single nucleotide polymorphism (SNP) microarray was used to detect microdeletions or microduplications in the patient. Fluorescence in situ hybridization (FISH) was used to ascertain the origin of aberrant chromosomes. The karyotype of the patient was 46,XY,der(18), while both of his parents had a normal karyotype. SNP array identified a 1.23 Mb deletion at 18p11.32-pter (chr18: 136 227-1 370 501, hg19) and a 33.76 Mb duplication at 18q21.1-qter (chr18: 44 250 359-78 013 728, hg19) in the patient. Above finding was confirmed by dual-color FISH with one color for 18p and another for 18q. The patient presented with some common features of 18p deletion and 18q duplication including intellectual disability and growth retardation, in addition with some features of 18p deletion including pectus excavatum, short stature and growth hormone (GH) deficiency. The patient showed progressive improvement of stature with GH therapy. Comparison of patients with previously reported dup(18q)+del(18p) recombinations suggested that, even for patients with similar breakpoints, their phenotypes have ranged from normal to severe and there were no consistent findings. As aberrations involving double chromosomal segments often result in phenotypic variability, it has been difficult to correlate the genotype of our patient with his phenotype.
2009-10-20 | Placental protein 13 as a first trimester screening marker for aneuploidy
Abstract Objective To determine whether Placental Protein 13 (PP13) could be an additional marker in first trimester screening for aneuploidies. Methods To evaluate differences in multiples of the gestation‐specific normal median (MoMs), PP13 concentrations were measured in serum samples from Down syndrome, trisomy 18 and 13 affected pregnancies and euploid singleton pregnancies (four for each case matched for duration of storage, maternal weight and age). Results The PP13 MoM in Down syndrome cases ( n = 153) was 0.91 [not statistically significant from controls ( n = 853); P = 0.06; Wilcoxon rank sum test, two‐tail]. PP13 MoMs were decreased in trisomy 18 ( n = 38—median MoM 0.64; P < 0.0001) and trisomy 13 cases ( n = 23—median MoM 0.46; P < 0.0001). There was a slight upward trend in MoM values of the Down syndrome cases with gestational weeks. The PP13 MoM was significantly correlated with the pregnancy associated plasma protein‐A MoM and the free β‐subunit of human chorion gonadotrophin (fβ‐hCG) MoM. Conclusion PP13 does not seem to be a good marker for Down syndrome. PP13 MoMs are, however, significantly lower in trisomy 18 and 13 pregnancies. The addition of PP13 to the current screening test could be valuable for improving the discrimination of aneuploid from euploid pregnancies. Copyright © 2009 John Wiley & Sons, Ltd.
gene therapies
2026-08-19 | Chromosomal and genetic anomalies in fetuses with nuchal translucency between 3.0 and 3.4 mm: A systematic review and meta-analysis.
To report the prevalence of chromosomal anomalies in fetuses with a nuchal translucency (NT) between 3.0 and 3.4 mm and to assess the incremental yield of invasive prenatal diagnosis over cell-free DNA (cfDNA) in these fetuses. MEDLINE, EMBASE, and The Cochrane Library were searched. Inclusion criteria encompassed fetuses with an NT between 3.0 and 3.4 mm undergoing prenatal invasive testing or postnatal genetic assessment. The observed outcomes included common trisomies such as Trisomy 21, 18, and 13, sex chromosomal anomalies (SCAs), rare autosomal anomalies, copy number variants detected by chromosomal microarray (CMA), and single-gene disorders. We also reported the rate of anomalies potentially detectable by cfDNA. Finally, we planned to perform a subgroup analysis involving cases with isolated NT between 3.0 and 3.4 mm, including only cases undergoing detailed first-trimester ultrasound assessment. A random-effects meta-analysis of proportions was utilized to analyze the data. Seventeen studies (7007 fetuses) were included. In fetuses with NT measurements between 3.0 and 3.4 mm, chromosomal anomalies were identified in 13.1% (95% CI 9.3-17.3). Common trisomies included Trisomy 21 at 8.0% (95% CI 5.1-11.5), Trisomy 18 at 1.0% (95% CI 0.6-1.7), and Trisomy 13 at 0.52% (95% CI 0.2-1.0) of all chromosomal anomalies. SCAs occurred in 0.58% (95% CI 0.4-0.8), while rare autosomal trisomies and pathogenic or likely pathogenic copy number variants (CNVs) were found in 0.27% (95% CI 0.1-0.6) and 2.5% (95% CI 1.3-3.9), respectively. Additionally, single-gene disorders detected via NGS/WES were reported in 5.7% (95% CI 3.3-8) of cases with NT between 3.0 and 3.4 mm. When examining only fetuses with an isolated NT between 3.0 and 3.4 mm, all chromosomal anomalies were identified in 12.4% (95% CI 7.9-17.7). Fetuses with an NT between 3.0 and 3.4 mm showed a high rate of chromosomal anomalies and CNVs, most of which could potentially be detected through cfDNA.
2026-05-08 | Embryonic reference values for nuchal translucency thickness and ductus venosus blood flow at 8-10 + 6 gestational weeks.
To measure embryonic nuchal translucency (NT) thickness and ductus venosus (DV) blood flow indices using transvaginal two-dimensional sonography and Doppler ultrasound at 8-10 + 6 weeks. Transvaginal scans were performed for 149 normal and three abnormal embryos (trisomy 18 with ventricular septal defect (VSD), tricuspid insufficiency (TR), and intrauterine fetal death with trisomy 21) at 8-10 + 6 weeks. NT thickness, S wave (cm/s), D wave (cm/s), "a" wave (cm/s), S/a, pulsatility index (PI), and resistance index (RI) of DV were measured, and reference values for each parameter were determined. NT, S, D, S/a, PI, and RI increased linearly with advancing gestation (p < 0.01). The 'a' (mean, 5.55 cm/s; SD, 1.8 cm/s) value was constant at 8-10 + 6 weeks of gestation. There were significant linear correlations between NT, S, D, S/a, PI, and RI, and crown-rump length (CRL) (p < 0.01). The "a" value remained unchanged with increasing CRL during this period. NT thickness (2.8 mm) in the trisomy 18 patient with VSD was high at 10 + 6 weeks, and reversed "a" wave was evident in the patient with TR at 10 + 1 weeks. In a fetus with intrauterine fetal death with trisomy 21 at 11 weeks and 6 days, NT thickness was 2.1 mm, and reversed DV flow was noted at 9 weeks and 6 days. Our results provide reference values for NT thickness and DV flow parameters, which may advance our understanding of embryonic growth and promote earlier prenatal diagnosis of chromosome abnormalities and/or cardiac anomalies before 11 weeks.
2026-03-24 | Interplay between DYRK1A dosage and aneuploidy-induced neuropathology in Down syndrome
A reduction in the number of neurons and an increased susceptibility to apoptosis are one of the characteristic features observed in Down syndrome (DS). However, the multifaceted actions of chromosomal aneuploidy hinder the elucidation of the underlying mechanism. Here, using neurons and astrocytes differentiated from patient-derived induced pluripotent stem cells (iPSCs), we aimed to clarify the neuropathology of DS by focusing on aneuploidy-associated stress and the dosage effects of specific genes. Human chromosomal trisomies 13, 18, and 21 exert a stress response on neurons, resulting in the accumulation of protein aggregates. In addition, DYRK1A overdosage in trisomy 21 astrocytes causes intrinsic activation of the NLRP3 inflammasome, which leads to the release of inflammatory cytokines. These dual actions reciprocally interact and enhance neuronal apoptosis in trisomy 21. Notably, correction of DYRK1A copy number successfully rescued apoptotic neural death in combination with a chemical chaperone treatment. Our study provides insights into the neuropathological mechanism of DS and its potential therapeutic strategy.
2026-02-09 | Maternal mixed UPD3 and a homozygous PLXNA1 c.2497G>C variant in a fetus with severe anomalies.
Non-invasive prenatal testing (NIPT) is widely used for screening common fetal aneuploidies such as trisomy 21 (T21), trisomy 18 (T18), and trisomy 13 (T13). However, its utility in detecting trisomy 3 (T3) has been rarely reported. Furthermore, uniparental disomy (UPD) involving chromosome 3 is a rare genetic condition with potential phenotypic consequences. NIPT indicated a high risk for fetal T3. This finding was further investigated using copy number variation (CNV) analysis via trio-based chromosomal microarray analysis (trio-CMA). Subsequent trio-based whole-genome sequencing (trio-WGS) identified a homozygous variant in PLXNA1 associated with a putative autosomal recessive disorder in the fetus. The detected variant was validated by Sanger sequencing in the parents. NIPT revealed a fetal Z-score (27.22) for T3. Trio-CMA ruled out T3 but confirmed mixed maternal UPD3. Trio-WGS identified a homozygous PLXNA1 variant (NM_032242.3:c.2497G>C, p.Ala833Pro) in the fetus, inherited from the heterozygous mother. The observed severe fetal phenotype was partial consistent with the molecular findings of mixed UPD3 and the homozygous PLXNA1 variant, indicating that this variant may represent a potential pathogenic cause. While NIPT can signal a high risk for rare aneuploidies, definitive diagnosis requires invasive prenatal testing. Discrepancies between NIPT and fetal tissue analyses may arise from confined placental mosaicism (CPM). We propose a model in which nondisjunction of chromosome 3 during germ cell formation led to trisomy, followed by a postzygotic self-correction event, resulting in mixed maternal UPD3 and increased risk of autosomal recessive disorders.
2026-01-01 | Frequency of chromosomal alterations identified in peripheral blood karyotypes at the genetics and genomics Laboratory of Hospital del Niño Dr. José Renán Esquivel (2015–2019)
To describe the chromosomal alterations found in peripheral blood karyotypes performed at the Genetics and Genomics Laboratory of the Hospital del Niño of Panama, Dr. José Renán Esquivel, during the years 2015 to 2019. A descriptive, cross-sectional study with a quantitative approach was conducted. During this period, a total of 835 chromosomal analyses were performed on peripheral blood lymphocytes. Of these, 336 patients presented some type of chromosomal alteration. Among them, 85% (285 patients) had numerical chromosomal alterations, while 15% (51 patients) had structural chromosomal alterations, with numerical alterations being the most frequent. Among numerical alterations, Trisomy 21 (Down Syndrome) was the most common, representing 85% of these cases. Other alterations included Turner Syndrome (5%), Trisomy 13 (4%), Trisomy 18 (3%), and less frequently, Klinefelter Syndrome and mosaicism cases (1%). Regarding structural chromosomal alterations, the most frequent were Robertsonian translocations (31%), followed by heterochromatin+ (20%), deletions (16%), and inversions (12%). Less common alterations included duplications, isochromosomes, additional material, insertions, and fragile sites. The findings of this study partially align with previous research conducted in Argentina (Aiassa and Gorlat, 2010) and Chile (Estay et al., 2007). These studies also reported a predominance of numerical alterations, particularly Trisomy 21. However, differences were observed in the frequency of structural alterations: deletions were more common in Argentina, whereas translocations were more frequent in Chile and Panama. Numerical chromosomal alterations, particularly Trisomy 21, were the most common in the studied population, highlighting the importance of early cytogenetic diagnosis in pediatric patients.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
0 orphan drug designations.
0 orphan drug designations.
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI’s forecasts to outperform average preclinical success rates. Whether you’re expanding your R&D pipeline, evaluating a partnership, or simply have a question — we’d love to hear from you.